This COST action aims to unite a currently fragmented critical mass of academic, clinical, and industry expertise to improve both the fundamental understanding and translational potential of perinatal derivatives. It includes participants with extensive know-how in basic research, clinical trials, regulatory affairs, and biomedical industry. SPRINT is joining forces to strengthen knowledge in the field and overcome the bottlenecks of translation to enable innovative therapeutic applications of perinatal-derived tissues, cells, and factors. Within Action Working Group 2, the IMR team worked to review preclinical studies in animal models to assess the efficacy of therapeutic interventions and identify research gaps, resulting in three papers co-authored by IMR team members.